Wellington Biomedical Innovation III Access LLC, a Delaware LLC formed in 2026, filed a new Form D for an indefinite offering under Regulation 3(c)(7) for qualified institutional buyers. The fund is in pre-first-close stage with Goldman Sachs & Co. LLC listed as placement agent.
Note: Feeder or access fund structure indicated; Wellington Biomedical Innovation III primary fund details not in this filing.
Computed from every Form D fund launch on EDGAR since late 2024, not sampled. Amounts are the stated offering size; indefinite offerings are excluded.
Earlier and related filings by the same issuer and sponsor. All Wellington Biomedical Innovation vehicles →
WELLINGTON MANAGEMENT COMPANY LLP
Website and main-office phone from Form ADV. Subscribe to unlock
The administrator, auditor, custodian and prime broker named on this adviser's 40 other funds: whether a new mandate here is a displacement or a greenfield. Subscribe to unlock
12 other filings on EDGAR under this adviser, with size, strategy and date. Subscribe to unlock
| Jody Flaws | Executive Officer |
| Scott Huff | Executive Officer |
| Richard A. Ruffer | Executive Officer |
[email protected] · observed Work emails for the people on the filing, where the firm publishes or patterns them, labelled by confidence — subscribers
Signed by Richard Ruffer, Manager of the Issuer's Managing Member.
Placement agents / sales compensation: Goldman Sachs & Co. LLC
The issuer's phone number and address from the filing are shown to subscribers. See plans.
